Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases

Takuto Takahashi, John R Prensner, Caroline D Robson, Katherine A Janeway, Brenda J Weigel

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Systemic therapy for pediatric desmoid tumors has been challenged by a lack of high-quality clinical evidence and potential adverse effects. The gamma-secretase inhibitor nirogacestat has shown promising efficacy in adults. We report four cases of pediatric and young adult desmoid tumor patients (three with familial adenomatous polyposis [FAP] syndrome) who received nirogacestat on compassionate use. After a median of 13.5 months (range 6-18), three had durable benefit: a complete response (Case 1); a partial response (Case 2); stable disease (Case 3). The fourth had disease progression after a partial response. No patient experienced grade 3 or 4 adverse events.

Original languageEnglish (US)
Article numbere28636
Pages (from-to)e28636
JournalPediatric blood & cancer
Volume67
Issue number10
DOIs
StatePublished - Oct 2020

Bibliographical note

Funding Information:
We wish to express our gratitude to SpringWorks Therapeutics for offering compassionate use of nirogacestat to the patients. We gratefully acknowledge the patients and families who participated in this work and permitted this manuscript to be published.

Publisher Copyright:
© 2020 Wiley Periodicals LLC

Keywords

  • desmoid tumor
  • nirogacestat
  • pediatric

PubMed: MeSH publication types

  • Case Reports
  • Journal Article

Fingerprint

Dive into the research topics of 'Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases'. Together they form a unique fingerprint.

Cite this